Natural Cycles

GLP-1 Receptor Agonists Show Promise for PCOS Treatment in Early Studies

- Weight loss drugs like semaglutide are demonstrating potential benefits for women with polycystic ovary syndrome (PCOS), a condition affecting 5-6 million U.S. women with no standard treatment available. - A 2023 study found that 80% of obese PCOS patients treated with semaglutide achieved at least 5% weight loss and normalized menstrual cycles after six months of treatment. - Early clinical trials and patient surveys indicate GLP-1 drugs may improve insulin sensitivity, regulate periods, and reduce PCOS-related symptoms including hair loss and mental health issues. - Larger, longer-term studies are needed to establish safety, efficacy, and optimal treatment protocols before these medications can become standard PCOS therapy.